SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 75,000 Shares of Company Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 75,000 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $25.30, for a total transaction of $1,897,500.00. Following the completion of the sale, the chief executive officer owned 304,256 shares of the company’s stock, valued at $7,697,676.80. This represents a 19.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Laura Francis also recently made the following trade(s):

• On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The shares were sold at an average price of $20.05, for a total value of $762,020.30.
• On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The shares were sold at an average price of $20.12, for a total value of $522,556.64.
• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total value of $1,009,662.64.

SiBone Stock Down 0.1%

Shares of SIBN traded down $0.03 during trading hours on Friday, hitting $24.24. 683,472 shares of the company were exchanged, compared to its average volume of 638,581. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.55 and a current ratio of 7.58. The company has a market cap of $1.09 billion, a PE ratio of -78.19 and a beta of 0.64. The firm’s 50 day moving average is $19.71 and its 200-day moving average is $16.56. SiBone has a 52 week low of $11.48 and a 52 week high of $25.92.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. The business had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. On average, equities research analysts forecast that SiBone will post -0.34 EPS for the current fiscal year.

Hedge Funds Weigh In On SiBone

A number of large investors have recently modified their holdings of SIBN. D.A. Davidson & CO. lifted its stake in shares of SiBone by 2.8% during the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock valued at $711,000 after acquiring an additional 1,038 shares during the period. First Light Asset Management LLC increased its position in SiBone by 51.8% in the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after purchasing an additional 2,774,795 shares during the period. Squarepoint Ops LLC increased its position in SiBone by 40.3% in the second quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock worth $1,928,000 after purchasing an additional 33,947 shares during the period. VELA Investment Management LLC raised its holdings in SiBone by 7.4% during the 2nd quarter. VELA Investment Management LLC now owns 201,094 shares of the company’s stock worth $3,282,000 after purchasing an additional 13,934 shares during the last quarter. Finally, Corient Private Wealth LP raised its holdings in SiBone by 119.6% during the 2nd quarter. Corient Private Wealth LP now owns 43,946 shares of the company’s stock worth $717,000 after purchasing an additional 23,938 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on SIBN. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Citigroup reaffirmed a “market outperform” rating on shares of SiBone in a research note on Tuesday. Truist Financial upped their price objective on shares of SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Needham & Company LLC reduced their price objective on SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, UBS Group increased their target price on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.00.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.